CL2015001085A1 - Formulacion de liberación prolongada que comprende oprozomib y ademas uno o mas polimeros farmaceuticamente aceptables; metodo de preparacion de la formulacion; metodo para tratar cancer. - Google Patents
Formulacion de liberación prolongada que comprende oprozomib y ademas uno o mas polimeros farmaceuticamente aceptables; metodo de preparacion de la formulacion; metodo para tratar cancer.Info
- Publication number
- CL2015001085A1 CL2015001085A1 CL2015001085A CL2015001085A CL2015001085A1 CL 2015001085 A1 CL2015001085 A1 CL 2015001085A1 CL 2015001085 A CL2015001085 A CL 2015001085A CL 2015001085 A CL2015001085 A CL 2015001085A CL 2015001085 A1 CL2015001085 A1 CL 2015001085A1
- Authority
- CL
- Chile
- Prior art keywords
- formulation
- oprozomib
- preparation
- pharmaceutically acceptable
- treat cancer
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 2
- 238000000034 method Methods 0.000 title 2
- 239000000203 mixture Substances 0.000 title 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 108010064641 ONX 0912 Proteins 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- SWZXEVABPLUDIO-WSZYKNRRSA-N n-[(2s)-3-methoxy-1-[[(2s)-3-methoxy-1-[[(2s)-1-[(2r)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide Chemical compound N([C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)[C@]1(C)OC1)C(=O)C1=CN=C(C)S1 SWZXEVABPLUDIO-WSZYKNRRSA-N 0.000 title 1
- 229950005750 oprozomib Drugs 0.000 title 1
- 229920000642 polymer Polymers 0.000 title 1
- 230000002035 prolonged effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261717975P | 2012-10-24 | 2012-10-24 | |
| US201261721244P | 2012-11-01 | 2012-11-01 | |
| US201361793087P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015001085A1 true CL2015001085A1 (es) | 2015-08-28 |
Family
ID=50485877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015001085A CL2015001085A1 (es) | 2012-10-24 | 2015-04-24 | Formulacion de liberación prolongada que comprende oprozomib y ademas uno o mas polimeros farmaceuticamente aceptables; metodo de preparacion de la formulacion; metodo para tratar cancer. |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9295708B2 (instruction) |
| EP (1) | EP2912025A4 (instruction) |
| JP (1) | JP6505604B2 (instruction) |
| KR (1) | KR20150070406A (instruction) |
| CN (1) | CN104968650A (instruction) |
| AP (1) | AP3681A (instruction) |
| AR (1) | AR093126A1 (instruction) |
| AU (1) | AU2013334258A1 (instruction) |
| BR (1) | BR112015008572A2 (instruction) |
| CA (1) | CA2888039A1 (instruction) |
| CL (1) | CL2015001085A1 (instruction) |
| CR (1) | CR20150266A (instruction) |
| EA (1) | EA201590797A1 (instruction) |
| HK (2) | HK1215709A1 (instruction) |
| IL (1) | IL238244A0 (instruction) |
| IN (1) | IN2015DN03921A (instruction) |
| MX (1) | MX2015005069A (instruction) |
| PE (1) | PE20151051A1 (instruction) |
| PH (1) | PH12015500823A1 (instruction) |
| SG (1) | SG11201502849XA (instruction) |
| TN (1) | TN2015000135A1 (instruction) |
| TW (1) | TW201422255A (instruction) |
| UY (1) | UY35091A (instruction) |
| WO (1) | WO2014066681A1 (instruction) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| AU2016278846B2 (en) * | 2015-06-19 | 2021-08-05 | Biotie Therapies, Inc. | Controlled-release tozadenant formulations |
| CN105949279A (zh) * | 2016-04-27 | 2016-09-21 | 浙江大学 | 蛋白酶体抑制剂Oprozomib及其类似物的制备方法 |
| CN109641860B (zh) | 2016-06-29 | 2024-05-28 | 科智生命科学公司 | 制备肽环氧酮免疫蛋白酶体抑制剂和其前体的方法 |
| US20180078532A1 (en) * | 2016-09-21 | 2018-03-22 | Amgen Inc. | Immediate release formulations for oprozomib |
| US20180161279A1 (en) * | 2016-12-14 | 2018-06-14 | Amgen Inc. | Gastro-retentive modified release dosage forms for oprozomib and process to make thereof |
| EP3694878A1 (en) | 2017-09-14 | 2020-08-19 | GlaxoSmithKline Intellectual Property Development Limited | Combination treatment for cancer |
| CN110357940A (zh) * | 2019-08-02 | 2019-10-22 | 苏州艾和医药科技有限公司 | 奥普佐米合成工艺研究 |
| KR20250008774A (ko) | 2022-05-11 | 2025-01-15 | 셀진 코포레이션 | T 세포 요법 및 그의 생산과 관련된 방법 및 용도 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5126145A (en) * | 1989-04-13 | 1992-06-30 | Upsher Smith Laboratories Inc | Controlled release tablet containing water soluble medicament |
| JPH06199657A (ja) * | 1992-12-10 | 1994-07-19 | Sumitomo Pharmaceut Co Ltd | 徐放性製剤 |
| WO1998010779A1 (en) | 1996-09-13 | 1998-03-19 | New York University | Method for treating parasitic diseases with proteasome inhibitors |
| JP4748839B2 (ja) * | 1999-03-25 | 2011-08-17 | 大塚製薬株式会社 | シロスタゾール製剤 |
| DE60221642T3 (de) * | 2001-02-12 | 2017-10-26 | Wyeth LLC (n.d.Ges.d. Staates Delaware) | O-desmethyl-venlafaxine succinat salz |
| US8119154B2 (en) * | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| MY145757A (en) * | 2005-11-09 | 2012-04-13 | Proteolix Inc | Compounds for enzyme inhibition |
| US20100172988A1 (en) * | 2006-01-10 | 2010-07-08 | Kissei Pharmaceutical Co., Ltd. | Sustained release preparation and method for production thereof |
| WO2008140782A2 (en) | 2007-05-10 | 2008-11-20 | Proteolix, Inc. | Compounds for enzyme inhibition |
| CL2008002966A1 (es) * | 2007-10-04 | 2010-06-25 | Onyx Therapeutics Inc | Compuesto tetrapeptido ceto-epoxido cristalino; sal citrato cristalina del compuesto; metodos de preparacion; compuesto intermediario cristalino; metodo de preparacion; y uso para tratar cancer, enfermedad autoinmune, afeccion relacionada con trasplante, enfermedad neurodegenerativa, afeccion asociada con fibrosis, entre otros. |
| AR075899A1 (es) * | 2009-03-20 | 2011-05-04 | Onyx Therapeutics Inc | Tripeptidos epoxicetonas cristalinos inhibidores de proteasa |
-
2013
- 2013-10-22 UY UY0001035091A patent/UY35091A/es not_active Application Discontinuation
- 2013-10-22 TW TW102138163A patent/TW201422255A/zh unknown
- 2013-10-24 CA CA2888039A patent/CA2888039A1/en not_active Abandoned
- 2013-10-24 KR KR1020157013739A patent/KR20150070406A/ko not_active Withdrawn
- 2013-10-24 MX MX2015005069A patent/MX2015005069A/es unknown
- 2013-10-24 EP EP13849834.0A patent/EP2912025A4/en not_active Withdrawn
- 2013-10-24 CN CN201380067772.0A patent/CN104968650A/zh active Pending
- 2013-10-24 HK HK16103699.0A patent/HK1215709A1/zh unknown
- 2013-10-24 AR ARP130103868A patent/AR093126A1/es unknown
- 2013-10-24 WO PCT/US2013/066679 patent/WO2014066681A1/en active Application Filing
- 2013-10-24 JP JP2015539810A patent/JP6505604B2/ja not_active Expired - Fee Related
- 2013-10-24 EA EA201590797A patent/EA201590797A1/ru unknown
- 2013-10-24 AU AU2013334258A patent/AU2013334258A1/en not_active Abandoned
- 2013-10-24 HK HK15108858.7A patent/HK1208222A1/xx unknown
- 2013-10-24 IN IN3921DEN2015 patent/IN2015DN03921A/en unknown
- 2013-10-24 PE PE2015000537A patent/PE20151051A1/es not_active Application Discontinuation
- 2013-10-24 BR BR112015008572A patent/BR112015008572A2/pt not_active Application Discontinuation
- 2013-10-24 SG SG11201502849XA patent/SG11201502849XA/en unknown
- 2013-10-24 AP AP2015008387A patent/AP3681A/xx active
- 2013-10-24 US US14/062,759 patent/US9295708B2/en not_active Expired - Fee Related
-
2015
- 2015-04-08 TN TNP2015000135A patent/TN2015000135A1/fr unknown
- 2015-04-12 IL IL238244A patent/IL238244A0/en unknown
- 2015-04-15 PH PH12015500823A patent/PH12015500823A1/en unknown
- 2015-04-24 CL CL2015001085A patent/CL2015001085A1/es unknown
- 2015-05-20 CR CR20150266A patent/CR20150266A/es unknown
-
2016
- 2016-01-28 US US15/008,634 patent/US20160213610A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1215709A1 (zh) | 2016-09-09 |
| IL238244A0 (en) | 2015-06-30 |
| US20140113855A1 (en) | 2014-04-24 |
| BR112015008572A2 (pt) | 2017-07-04 |
| EA201590797A1 (ru) | 2016-02-29 |
| US9295708B2 (en) | 2016-03-29 |
| KR20150070406A (ko) | 2015-06-24 |
| AP3681A (en) | 2016-04-19 |
| AR093126A1 (es) | 2015-05-20 |
| WO2014066681A1 (en) | 2014-05-01 |
| HK1208222A1 (en) | 2016-02-26 |
| CR20150266A (es) | 2015-08-14 |
| JP6505604B2 (ja) | 2019-04-24 |
| US20160213610A1 (en) | 2016-07-28 |
| AP2015008387A0 (en) | 2015-04-30 |
| PH12015500823A1 (en) | 2015-06-22 |
| IN2015DN03921A (instruction) | 2015-10-02 |
| JP2015535255A (ja) | 2015-12-10 |
| PE20151051A1 (es) | 2015-08-03 |
| SG11201502849XA (en) | 2015-05-28 |
| UY35091A (es) | 2014-05-30 |
| AU2013334258A1 (en) | 2015-04-30 |
| CA2888039A1 (en) | 2014-05-01 |
| EP2912025A1 (en) | 2015-09-02 |
| EP2912025A4 (en) | 2016-06-08 |
| TN2015000135A1 (en) | 2016-10-03 |
| MX2015005069A (es) | 2015-07-17 |
| TW201422255A (zh) | 2014-06-16 |
| CN104968650A (zh) | 2015-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267997A (en) | Preparations, formulations and methods for treating eye diseases | |
| CL2015001085A1 (es) | Formulacion de liberación prolongada que comprende oprozomib y ademas uno o mas polimeros farmaceuticamente aceptables; metodo de preparacion de la formulacion; metodo para tratar cancer. | |
| CL2014003232A1 (es) | Formulaciones y métodos para la administración vaginal de antiprogestinas. | |
| BR112014023937A2 (pt) | composição farmacêutica, agente farmacêutico de combinação e método de tratamento | |
| IL239022B (en) | Tetracycline topical formulations, preparation and uses thereof | |
| BR112014009634A2 (pt) | preparação e agente terapêutico | |
| EP2988781A4 (en) | Compositions and methods for the therapy and diagnosis of influenza | |
| ZA201408119B (en) | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof | |
| BR112015002524A2 (pt) | derivados de alquilpirimidina para o tratamento de infecções virais e outras doenças. | |
| CO6940374A2 (es) | Composiciones, usos y métodos para tratamiento de trastornos y enfermedades metabólicas | |
| EP2890440A4 (en) | DEVICES AND METHOD FOR THE TREATMENT OF VASCULAR DISEASES | |
| HUE039864T2 (hu) | Gyógyászati készítmények CFTR-közvetítette betegségek kezelésére | |
| BR112015000437A2 (pt) | imunoconjugados, formulação farmacêutica, métodos de tratamento e de inbir a proliferação de uma célula | |
| PT2968172T (pt) | Formulação estabilizada de vitamina d de liberação modificada e método de administração da mesma | |
| EP2811981A4 (en) | IMPROVED ADJUVANT FORMULATIONS COMPRISING TLR4 AGONISTS AND METHODS OF USE | |
| LT3292875T (lt) | Kompozicijos ir būdai, skirti ligų gydymui | |
| EP3122754A4 (en) | Use of the fl118 core chemical structure platform to generate fl118 derivatives for treatment of human disease | |
| HRP20190318T1 (hr) | Farmaceutski ili kozmetički pripravak za liječenje alopecije | |
| HRP20181364T1 (hr) | Aminotriazolopiridin, namijenjen upotrebi u liječenju upale, te njegovi farmacetski pripravci | |
| BR112015006937A2 (pt) | formulações espumantes para cuidar da pele. | |
| PL2729008T3 (pl) | Systemy, sposoby i formulacje do leczenia raka | |
| PT2859896T (pt) | Composições farmacêuticas para o tratamento de distúrbios musculares | |
| BR112015014885A2 (pt) | combinação de agentes ativos, composição cosmética e/ou dermatológica e processo para a preparação de uma composição de agentes ativos. | |
| BR112014031512A2 (pt) | composição cosmética e método para o tratamento cosmético. | |
| CL2014002951A1 (es) | (r)-nifuratel; formulacion farmaceutica que lo contiene; y proceso para fabricar (r)-nifuratel y (s)-nifuratel. |